Brady Marian C, Kelly Helen, Godwin Jon, Enderby Pam, Campbell Pauline
Nursing, Midwifery and Allied Health Professions Research Unit, Glasgow Caledonian University, 6th Floor Govan Mbeki Building, Cowcaddens Road, Glasgow, UK, G4 0BA.
Cochrane Database Syst Rev. 2016 Jun 1;2016(6):CD000425. doi: 10.1002/14651858.CD000425.pub4.
Aphasia is an acquired language impairment following brain damage that affects some or all language modalities: expression and understanding of speech, reading, and writing. Approximately one third of people who have a stroke experience aphasia.
To assess the effects of speech and language therapy (SLT) for aphasia following stroke.
We searched the Cochrane Stroke Group Trials Register (last searched 9 September 2015), CENTRAL (2015, Issue 5) and other Cochrane Library Databases (CDSR, DARE, HTA, to 22 September 2015), MEDLINE (1946 to September 2015), EMBASE (1980 to September 2015), CINAHL (1982 to September 2015), AMED (1985 to September 2015), LLBA (1973 to September 2015), and SpeechBITE (2008 to September 2015). We also searched major trials registers for ongoing trials including ClinicalTrials.gov (to 21 September 2015), the Stroke Trials Registry (to 21 September 2015), Current Controlled Trials (to 22 September 2015), and WHO ICTRP (to 22 September 2015). In an effort to identify further published, unpublished, and ongoing trials we also handsearched the International Journal of Language and Communication Disorders (1969 to 2005) and reference lists of relevant articles, and we contacted academic institutions and other researchers. There were no language restrictions.
Randomised controlled trials (RCTs) comparing SLT (a formal intervention that aims to improve language and communication abilities, activity and participation) versus no SLT; social support or stimulation (an intervention that provides social support and communication stimulation but does not include targeted therapeutic interventions); or another SLT intervention (differing in duration, intensity, frequency, intervention methodology or theoretical approach).
We independently extracted the data and assessed the quality of included trials. We sought missing data from investigators.
We included 57 RCTs (74 randomised comparisons) involving 3002 participants in this review (some appearing in more than one comparison). Twenty-seven randomised comparisons (1620 participants) assessed SLT versus no SLT; SLT resulted in clinically and statistically significant benefits to patients' functional communication (standardised mean difference (SMD) 0.28, 95% confidence interval (CI) 0.06 to 0.49, P = 0.01), reading, writing, and expressive language, but (based on smaller numbers) benefits were not evident at follow-up. Nine randomised comparisons (447 participants) assessed SLT with social support and stimulation; meta-analyses found no evidence of a difference in functional communication, but more participants withdrew from social support interventions than SLT. Thirty-eight randomised comparisons (1242 participants) assessed two approaches to SLT. Functional communication was significantly better in people with aphasia that received therapy at a high intensity, high dose, or over a long duration compared to those that received therapy at a lower intensity, lower dose, or over a shorter period of time. The benefits of a high intensity or a high dose of SLT were confounded by a significantly higher dropout rate in these intervention groups. Generally, trials randomised small numbers of participants across a range of characteristics (age, time since stroke, and severity profiles), interventions, and outcomes.
AUTHORS' CONCLUSIONS: Our review provides evidence of the effectiveness of SLT for people with aphasia following stroke in terms of improved functional communication, reading, writing, and expressive language compared with no therapy. There is some indication that therapy at high intensity, high dose or over a longer period may be beneficial. HIgh-intensity and high dose interventions may not be acceptable to all.
失语症是脑损伤后获得性语言障碍,影响部分或全部语言模式:言语的表达与理解、阅读和写作。约三分之一的中风患者会出现失语症。
评估言语和语言治疗(SLT)对中风后失语症的效果。
我们检索了Cochrane中风组试验注册库(最后检索时间为2015年9月9日)、CENTRAL(2015年第5期)及其他Cochrane图书馆数据库(CDSR、DARE、HTA,截至2015年9月22日)、MEDLINE(1946年至2015年9月)、EMBASE(1980年至2015年9月)、CINAHL(1982年至2015年9月)、AMED(1985年至2015年9月)、LLBA(1973年至2015年9月)以及SpeechBITE(2008年至2015年9月)。我们还检索了主要试验注册库以查找正在进行的试验,包括ClinicalTrials.gov(截至2015年9月21日)、中风试验注册库(截至2015年9月21日)、当前对照试验(截至2015年9月22日)以及WHO ICTRP(截至2015年9月22日)。为努力识别更多已发表、未发表及正在进行的试验,我们还手工检索了《国际语言与交流障碍杂志》(1969年至2005年)以及相关文章的参考文献列表,并联系了学术机构和其他研究人员。无语言限制。
随机对照试验(RCT),比较SLT(旨在改善语言和交流能力、活动及参与度的正式干预措施)与无SLT;社会支持或刺激(提供社会支持和交流刺激但不包括针对性治疗干预的干预措施);或另一种SLT干预(在持续时间、强度、频率、干预方法或理论方法上不同)。
我们独立提取数据并评估纳入试验的质量。我们向研究者索要缺失数据。
本综述纳入了57项RCT(74个随机对照比较),涉及3002名参与者(有些出现在不止一个比较中)。27个随机对照比较(1620名参与者)评估了SLT与无SLT;SLT对患者的功能交流(标准化均数差(SMD)0.28,95%置信区间(CI)0.06至0.49,P = 0.01)、阅读、写作及表达性语言产生了临床和统计学上的显著益处,但(基于较少数量)随访时益处不明显。9个随机对照比较(447名参与者)评估了SLT与社会支持及刺激;荟萃分析未发现功能交流存在差异的证据,但退出社会支持干预的参与者比退出SLT的更多。38个随机对照比较(1242名参与者)评估了两种SLT方法。与接受低强度、低剂量或较短疗程治疗的失语症患者相比,接受高强度、高剂量或较长疗程治疗的患者功能交流明显更好。这些干预组中较高的脱落率混淆了高强度或高剂量SLT的益处。一般来说,试验在一系列特征(年龄、中风后时间及严重程度概况)、干预措施和结局方面随机分配的参与者数量较少。
我们的综述提供了证据,表明与不治疗相比,SLT对中风后失语症患者在改善功能交流、阅读、写作及表达性语言方面是有效的。有迹象表明高强度、高剂量或较长疗程的治疗可能有益。高强度和高剂量干预可能并非对所有人都可接受。